Site-Specific Antibody-Drug Conjugates via Cysteine Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in achieving site-specific conjugation, leading to variability in drug-to-antibody ratio (DAR) and systemic toxicity, with non-specific conjugation methods affecting stability and pharmacokinetics.
Innovation Solution
The development of ADCs where the drug moiety is conjugated to specific interchain cysteine residues, with substitutions of cysteine residues by other amino acids and modifications in the heavy chain, such as substitutions at positions 234 and 235, to enhance site-specificity and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If non-specific conjugation methods are used (lysine side chains or reduced disulfide bonds), then manufacturing is easier, but drug-to-antibody ratio variability and systemic toxicity increase
Solution Approach 1:
The patent introduces site-specific cysteine residues at defined positions (e.g., hinge region, CH1, CL domains) to enable localized conjugation. This creates distinct conjugation zones with controlled drug attachment, ensuring uniform DAR while maintaining manufacturing feasibility through targeted chemical reactions at specific antibody locations.
Solution Approach 2:
The patent modifies antibody structure by introducing specific cysteine mutations (e.g., L234C, L235C substitutions) and controlling oxidation conditions to generate defined numbers of sulfhydryl groups. These parameter changes in amino acid sequence and reaction conditions enable precise control over DAR and reduce batch-to-batch variability.
2Ease of manufacture
If non-specific conjugation methods are used, then manufacturing is easier, but systemic toxicity increases
Solution Approach 1:
By restricting conjugation to specific cysteine residues at defined antibody locations (hinge region, heavy or light chains), the patent ensures uniform drug distribution and prevents off-target effects. This localized approach reduces systemic toxicity while maintaining ease of manufacture through standardized site-specific protocols.
Solution Approach 2:
The patent employs controlled oxidation conditions and chemical environments to selectively activate cysteine residues only at intended conjugation sites. This controlled chemical 'pressure' ensures drugs attach only where designed, preventing non-specific binding and reducing systemic toxicity.
3Manufacturing precision
If site-specific conjugation is achieved through amino acid substitution, then DAR consistency improves, but device complexity increases
Solution Approach 1:
The patent introduces site-specific cysteine residues at defined positions (e.g., hinge region, CH1, CL domains) to enable localized conjugation. This creates distinct conjugation zones with controlled drug attachment, ensuring uniform DAR while maintaining manufacturing feasibility through targeted chemical reactions at specific antibody locations.
Solution Approach 2:
The patent modifies antibody structure by introducing specific cysteine mutations (e.g., L234C, L235C substitutions) and controlling oxidation conditions to generate defined numbers of sulfhydryl groups. These parameter changes in amino acid sequence and reaction conditions enable precise control over DAR and reduce batch-to-batch variability.
4Stability of the object's composition
If site-specific conjugation is achieved through amino acid substitution, then pharmacokinetic stability improves, but device complexity increases
Solution Approach 1:
The patent introduces site-specific cysteine residues at defined positions (e.g., hinge region, CH1, CL domains) to enable localized conjugation. This creates distinct conjugation zones with controlled drug attachment, ensuring uniform DAR while maintaining manufacturing feasibility through targeted chemical reactions at specific antibody locations.
Solution Approach 2:
The patent modifies antibody structure by introducing specific cysteine mutations (e.g., L234C, L235C substitutions) and controlling oxidation conditions to generate defined numbers of sulfhydryl groups. These parameter changes in amino acid sequence and reaction conditions enable precise control over DAR and reduce batch-to-batch variability.
Data Source
AI summary
Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.